Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,556.00
Bid: 12,548.00
Ask: 12,550.00
Change: 6.00 (0.05%)
Spread: 2.00 (0.016%)
Open: 12,570.00
High: 12,704.00
Low: 12,472.00
Prev. Close: 12,550.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-No U.S. rate rise until 2024?

Fri, 30th Apr 2021 10:07

* Europe's STOXX 600 up 0.1%

* Basic materials index worst performer, down 1%

* Barclays tumbles after cautious guidance

* Healthcare stock index leads gains up 0.8%

April 30 - Welcome to the home for real-time coverage of
markets brought to you by Reuters reporters. You can share your
thoughts with us at markets.research@thomsonreuters.com

NO U.S. RATE RISE UNTIL 2024? (0905 GMT)

A Fed tapering might be dangerous for equities, but we
should also ask ourselves if investors have already priced that
in.

UBS analysts have a pretty clear idea on the matter. They
expect “discussions on bond purchase tapering (by the Fed) to
surface in the second half of the year.”

But they “believe markets have largely priced in this
expectation.” In addition, they “do not expect any rate hike
until 2024.”

This would mean that equities will benefit from the
ultra-loose policy by the U.S. government, without worrying
about yields for a reasonable length of time.

But there are still reasons to expect more market turbulence
“as investors fret over rising inflation and the uneven global
progress in combating the pandemic,” UBS analysts say.

Bottom line, equities can rise further, but better to be
exposed to the “cyclical part of the market such as financials,
energy and value stocks.”

The chart shows the 10-year U.S. bond yields and the U.S.
dollar forward inflation-linked swap.

(Stefano Rebaudo)

*****

EARNINGS PROP UP STOXX, BUT BANKS UNDER PRESSURE (0745 GMT)

European stocks opened slightly higher as a batch of solid
company results boosted risk sentiment and offset worries about
rising bond yields.

The STOXX 600 index is up 0.2% with autos,
construction and materials stocks leading gains. Banks
are on the negative side, down 0.7% after yesterday’s
rise.

Barclays shares are down 5.5% after results.

Shares in AstraZeneca are rising 2.7% after the
company reports Q1 profit and sales ahead of expectations and
forecast higher sales in Q2.

Swiss Re stocks are up 4% after the company swang
to Q1 net profit, which was better than analysts expectations.

Investors will focus on today’s eurozone inflation figures
which might add more fuel to the fire of worries about rising
yields. Some analysts see upside risks, while most see a modest
decline in core numbers.

Eyes also on the U.S. core PCE Price Index with analysts
expecting a sizable jump.

(Stefano Rebaudo)

*****

EUROPE MAY OFFER STEER FOR WEEKEND CHEER (0658 GMT)

It's Europe's turn to confirm an improving global outlook,
a day after strong U.S. data and upbeat earnings lifted the S&P
500 to a record high close.

So far, so good: BNP Paribas, the euro zone's biggest listed
lender, posted a better-than-expected first-quarter profit while
Q1 profit at British bank Barclays more than doubled.

Next up is GDP data. Ahead of a euro-wide number released
later this morning, France revealed its economy grew a
stronger-than-expected 0.4% in Q1, having shrunk 1.4% in the
final quarter of 2020.

The euro zone economy is forecast to have shrunk 2% in the
first quarter year-on-year, versus a 4.9% fall in the final
quarter of last year.

A flash inflation estimate is also due; economists forecast
a 1.6% rise in the headline number in April versus a 1.3%
increase in March.

These figures may seem underwhelming compared to the United
States, which grew at a 6.4% annualized rate last quarter. Yet
sentiment appears to have turned a corner thanks to a pick-up in
the COVID vaccination rollout and signs economic activity has
held up relatively well in the face of ongoing restrictions.

That view perhaps is why Germany's 10-year Bund yield is
ending April almost 10 basis points higher -- even
as the U.S. equivalent is down 10 bps.

The recovery expectations, alongside upbeat earnings have
underpinned stocks, although Asian shares slipped on Friday and
European stock futures were a touch lower.

Copper, the other key growth barometer, also slipped after a
blistering rally to $10,000 a tonne, though it is on track for
the 12th monthly gain in the past 13 months.

Finally, the U.S. dollar skidded toward a fourth straight
weekly decline against a basket of peers, undermined by the
Federal Reserve's message of ultra-low rates for longer.

Key developments that should provide more direction to
markets on Friday:

- Earnings calendar: Exxon Mobil, Chevron, AbbVie, Charter
Communications, AstraZeneca.

-Nestle has bought the brands of vitamin and supplements
maker The Bountiful Company for $5.75 billion

-Darktrace lists in London but valuation well below reported
target

- U.S. March personal spending and income numbers due out.

- Credit Suisse board member Gottschling to exit after
Greensill, Archegos losses

- China official manufacturing PMI fell to 51.1 in April.

-British house prices posted the biggest single-month
increase since 2004

- Retailer Amazon posted record Q1 profits.

(Dhara Ranasinghe)

*****

EUROPE SUBDUED ON YIELDS RISE, CHINA WORRIES (0528 GMT)

European stock futures are slightly lower with no clear
trend emerging yet as a rise in yields is expected to put
pressure on some equity sectors while a mixed picture on Asian
markets dampens risk sentiment.

China stocks lost ground overnight after weak data on
concerns about a monetary policy tightening coupled with
Sino-U.S. tensions. U.S. President Joe Biden took aim at China
in his first speech to Congress, pledging to maintain a strong
U.S. military presence Indo-Pacific.

Biden's new spending plan and the dovish stance by the Fed
continue to support risk-appetite along with U.S. data released
yesterday, which showed American economic growth accelerated in
the first quarter.

(Stefano Rebaudo)

*****

More News
26 Jun 2024 08:40

TOP NEWS: AstraZeneca's Tagrisso plus chemo gets approval in China

(Alliance News) - AstraZeneca PLC on Wednesday celebrated the approval of Tagrisso plus chemotherapy for a cancer form in China, a day after a similar approval in Japan.

Read more
25 Jun 2024 09:05

TOP NEWS: AstraZeneca details mixed findings from cancer drug trials

(Alliance News) - AstraZeneca PLC on Tuesday announced a mixed bag of results for two of its leading cancer drugs Imfinzi and Tagrisso.

Read more
25 Jun 2024 07:48

LONDON BRIEFING: Mixed bag for Astra drug; Landsec ups Bluewater stake

(Alliance News) - London's FTSE 100 is set to tread water on Tuesday, with a slump for US tech shares overnight keeping a lid on enthusiasm.

Read more
25 Jun 2024 07:17

AstraZeneca posts mixed results from recent Imfinzi trials

(Sharecast News) - AstraZeneca announced contrasting results from two phase three trials involving its immunotherapy drug 'Imfinzi', or durvalumab, on Tuesday.

Read more
24 Jun 2024 15:40

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit

WASHINGTON, June 24 (Reuters) - The U.S. Supreme Court gave a boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies led by AstraZeneca to a lawsuit accusing them of illegally helping to fund terrorism that killed or injured hundreds of American troops and civilians in Iraq.

Read more
24 Jun 2024 14:56

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit

WASHINGTON, June 24 (Reuters) - The U.S. Supreme Court gave boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies led by AstraZeneca to a lawsuit accusing them of illegally helping to fund terrorism that killed or injured hundreds of American troops and civilians in Iraq.

Read more
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslodex, for the treatment of a form of breast cancer.

Read more
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

Read more
18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with inflation data and central bank decisions the key plot points as the week progresses.

Read more
18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.

Read more
17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
17 Jun 2024 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
17 Jun 2024 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.